BioCentury
ARTICLE | Financial News

Aminex raises $10M, starts Phase I cancer trial

June 22, 2018 7:02 PM UTC

Aminex Therapeutics Inc. (Seattle, Wash.) raised $10 million on June 20 in an untranched series B round. The company declined to name its investors.

The company also said it dosed the first patient in a Phase I trial of AMXT 1501, a small molecule polyamine uptake inhibitor, to treat solid tumors. An Aminex spokesperson told BioCentury data are due in 2H19. The 52-patient study is to evaluate AMXT 1501 alone or in combination with eflornithine...

BCIQ Company Profiles

Aminex Therapeutics Inc.